Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · October 07, 2024

Effectiveness and Tolerability of CGRP Monoclonal Antibodies vs OnabotulinumtoxinA in Patients With Chronic Migraine

European Journal of Neurology

 

Additional Info

European Journal of Neurology
Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan
Eur. J. Neurol. 2024 Sep 01;31(9)e16372, YF Wang, FC Yang, LA Chen, TY Chang, HC Su, CP Yang, YH Tu, YS Tzeng, SP Chen, JL Fuh, KL Lai, YH Ling, WT Chen, SJ Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading